The efficacy of anti-angiogenic agents (AAAs) in epithelial ovarian cancer (EOC) remains
unclear. Therefore, we conducted a systematic review and network meta-analysis (NMA) to …

Aggressive cancer cells gain robust tumor vascular mimicry (VM) capability that promotes
tumor growth and metastasis. VE-cadherin is aberrantly overexpressed in vasculogenic …

Highlights•Platinum-resistant diseases are related to worst prognosis in ovarian
cancers.•Neoadjuvant chemotherapy may be related to platinum resistance clinically.•Why …

Ovarian cancer progression involves multifaceted and variable tumor microenvironments
(TMEs), from the in situ carcinoma in the fallopian tube or ovary to dissemination into the …

Anti-angiogenic therapies (AATs) have been widely used for cancer treatment. But the
beneficial effects of AATs are short, because AAT-induced tumor revascularization facilitates …

Epithelial ovarian cancer (EOC) remains a significant cause of mortality among gynecologic
cancers, with the majority of cases being diagnosed at an advanced stage. Before targeted …

Metastasis is responsible for 90% of human cancer mortality, yet it remains a challenge to
model human cancer metastasis in vivo. Here we describe mouse models of high-grade …

Ovarian cancer with complete clinical response recurs with a high rate. Recurrence is
observed in almost 25% of cases with early-stage diseases and in more than 80% with more …

The naïve view of tumors as isolated islands of rogue cells has given way to a deeper
understanding of cancer as being closer to a foreign organ. This “organ” contains …

Background ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …